# Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)

> **NCT05489211** · PHASE2 · RECRUITING · sponsor: **AstraZeneca** · enrollment: 454 (estimated)

## Conditions studied

- Endometrial Cancer
- Gastric Cancer
- Metastatic Castration-resistant Prostate Cancer
- Ovarian Cancer
- Colorectal Cancer
- Urothelial Cancer
- Biliary Tract Cancer

## Interventions

- **DRUG:** Datopotamab deruxtecan (Dato-DXd)
- **DRUG:** Capecitabine
- **DRUG:** 5-Fluorouracil
- **DRUG:** Volrustomig
- **DRUG:** Carboplatin
- **DRUG:** Bevacizumab
- **DRUG:** Rilvegostomig
- **DRUG:** Prednisone/ prednisolone
- **DRUG:** Cisplatin

## Key facts

- **NCT ID:** NCT05489211
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-09-06
- **Primary completion:** 2027-10-01
- **Final completion:** 2027-10-01
- **Target enrollment:** 454 (ESTIMATED)
- **Last updated:** 2026-03-19

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05489211

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05489211, "Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)". Retrieved via AI Analytics 2026-06-16 from https://api.ai-analytics.org/clinical/NCT05489211. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*